Circulating tumor DNA as an early marker of therapeutic response in ...

ctDNA is detectable in a high proportion of treatment naïve mCRC patients. Early changes in ctDNA during first-line chemotherapy predict the later radiologic ...

This study examined the role of circulating tumor DNA (ctDNA) as a marker of early treatment response in patients with metastatic colorectal ...

Circulating tumor DNA as an early marker of therapeutic response in ...

We describe the potential role of ctDNA as an early predictor of treatment response of patients with metastatic colorectal cancer (mCRC) undergoing ...

Circulating tumor DNA as an early marker of therapeutic response in ...

In this work, we describe the potential role of ctDNA as an early predictor of treatment response of patients with metastatic colorectal cancer ...

Circulating tumor DNA as an early marker of therapeutic response in ...

Conclusions: ctDNA is detectable in a high proportion of treatment naïve mCRC patients. Early changes in ctDNA during first-line chemotherapy predict the later ...

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic ...

This study evaluated the relevancy of circulating tumor DNA (ctDNA) as a marker of treatment efficacy in metastatic colorectal cancer. The initial concentration ...

Early evaluation of circulating tumor DNA as marker of therapeutic ...

We assessed the potential role of serial circulating tumor DNA (ctDNA) as a biomarker to monitor treatment response to primary systemic therapy (PST) in breast ...

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic ...

We evaluated the applicability of early changes in circulating tumor DNA (ctDNA) as a marker of therapeutic efficacy. Experimental Design: This ...

Circulating tumor DNA as an early marker of therapeutic response in ...

Fingerprint. Dive into the research topics of 'Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer'.

Using Circulating Tumor DNA in Colorectal Cancer: Current and ...

Emerging data demonstrate that aside from a prognostic marker, ctDNA may also be a predictive biomarker of response to adjuvant therapy.

Early change in circulating tumor DNA as a potential predictor of ...

Collectively, these findings suggest that ctDNA might serve as a reliable predictive biomarker for early therapeutic response. In-depth research ...

12P Circulating tumor DNA as early marker of response to treatment ...

Circulating tumor DNA (ctDNA) represents a promising tool for diagnosis, prognosis and treatment monitoring of several malignant diseases. We aimed to ...

Early ctDNA response to chemotherapy. A potential surrogate ...

The results suggest that ctDNA response might serve as a surrogate marker for OS. If validated, it may have great implications on the approval ...

Tumor DNA in Blood May Signal Immunotherapy Response - NCI

A pilot study by NCI researchers suggests that tumor DNA circulating in the blood of patients with cancer might be a biological marker for determining, soon ...

Correlation between early dynamics in circulating tumour DNA and ...

Targeted sequencing analyses of cfDNA revealed dramatic changes in the clonal composition in response to treatment. Our study suggests that ...

Early plasma circulating tumor DNA (ctDNA) changes predict ...

Background Currently available biomarkers are imperfect in their ability to predict responses to the multiple first-line treatment options available for ...

Use of circulating tumor DNA (ctDNA) for early assessment of ...

Compared to tumor markers, ctDNA has a short half-life, which can allow for early response assessment, as shown by our study.

Monitoring of Early Changes of Circulating Tumor DNA in ... - Frontiers

We monitored circulating tumor DNA (ctDNA) as a potential liquid biopsy-based biomarker. We have investigated ctDNA changes plasma during the ...

Circulating Tumor DNA as a Biomarker for Monitoring Patients with ...

These biomarkers however, lack specificity for cancer and have poor sensitivity in detecting early recurrences and monitoring therapy ...

Regulatory implications of ctDNA in immuno-oncology for solid tumors

ctDNA may be used in early phase clinical trials to assist in evaluating antitumor response for investigational agents, but also has future ...